| |
Back to Drug index
Name: Propoxyphene hydrochloride
|
|
|
Percutaneous in-situ coronary venous arterialization is a new less invasive
alternative to CABG.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
Pregnancy Category C
C-IV controlled substance
Drug classes
Narcotic agonist analgesic
Therapeutic actions
Acts as agonist at specific opioid receptors in the CNS to produce
analgesia, euphoria, sedation; the receptors mediating these effects
are
thought to be the same as those mediating the effects of endogenous
opioids (enkephalins, endorphins).
Indications
Relief of mild to moderate pain
Contraindications/cautions
Contraindicated in the presence of hypersensitivity to narcotics,
pregnancy (neonatal withdrawal has occurred in infants born to mothers
who used narcotics during pregnancy; safety for use in pregnancy not
established), labor or delivery (especially when delivery of a
premature
infant is expected; administration of narcotics to the mother can
cause
respiratory depression of neonate; may prolong labor), lactation.
Use caution in the presence of renal or hepatic dysfunction, emotional
depression.
Adverse effects
- CNS: Dizziness, sedation, lightheadedness, headache, weakness,
euphoria,
dysphoria, minor visual disturbances
- GI: Nausea, vomiting, constipation, abdominal pain, liver dysfunction
- Dermatologic: Skin rashes
- Other: Tolerance and dependence, psychological dependence
|
|